Combined Modality Radioimmunotherapy For Non-Hodgkin's Lymphoma With Three Cycles Of 90Y-DOTA-Peptide-Lym-1, Paclitaxel and Cyclosporin A

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Diagnosis of non-Hodgkin's lymphoma (NHL) that has failed standard first-line
chemotherapy

- Measurable disease

- NHL tissue Lym-1 reactive in vitro

- Normocellular bone marrow as evidenced by less than 25% of the bone marrow being NHL
by bilateral bone marrow biopsy

- No bone marrow evidence of myelodysplastic syndrome

- HAMA titer negative

PATIENT CHARACTERISTICS:

Age:

- 18 and over

Performance status:

- Karnofsky 70-100%

Life expectancy:

- 3 to 6 months

Hematopoietic:

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 130,000/mm^3

Hepatic:

- Bilirubin no greater than 1.5 mg/dL

- AST no greater than 84 U/L

Renal:

- Creatinine less than 1.5 mg/dL OR

- Creatinine clearance at least 50 mL/min

Cardiovascular:

- LVEF at least 50%

Pulmonary:

- FEV1 at least 60% of predicted

- FVC at least 60% of predicted

- DLCO at least 50%

Other:

- No other prior malignancy within the past 5 years except for nonmelanoma skin cancer

- HIV negative

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

Endocrine therapy:

- Not specified

Radiotherapy:

- At least 4 weeks since prior external beam radiotherapy

Surgery:

- Not specified